Bloomberg are among many experts that predict the global medical cannabis market could be worth more than US$130 billion by 2029. Following suit of the global medical cannabis market, the Australian medicinal cannabis market is beginning to take flight.
At Australian Natural Therapeutics Group, we are uniquely well-positioned to supply the domestic market and become the first medicinal cannabis company in Australia to export cannabis flower for commercial purposes to the EU, having received the Good Manufacturing Practice (GMP) certification which certifies our medicinal cannabis meets the highest pharmaceutical quality standards worldwide, together with a permit for commercial cultivation granted by the Office of Drug Control and license from the Therapeutic Goods Administration (TGA).
We are also proud to have recently become the first Australian member of the Global Cannabis Partnership. The GCP is an international initiative that focuses on the establishment of worldwide corporate social responsibility (CSR) standards and informed consumption of legal cannabis.
What sets ANTG apart is our focus on quality, expertise and investment in research and development. We adhere to strict specialist standards and quality checks at every step of the cultivation, extraction and production process to ensure optimal quality and maximum medicinal benefit, with upgraded innovative cultivation facilities exceeding Australian standards. Our research partners include the University of Newcastle and the National Institute for Complementary Medicines at Western Sydney University amongst many others – together we progress to further strengthen the position of medicinal cannabis through continuous research and development.
“Research and development is at the core of this company, and we see it as our responsibility to provide robust evidence to healthcare professionals and the public. The body of evidence is extraordinary and it’s growing every single day.” – Matt Cantelo, Founder and CEO of ANTG.
Here at ANTG our overarching goal is to develop evidential and technological capabilities to instantly identify the right strain and dose of medical cannabis for general wellbeing, to treat specific health conditions, and develop preventive therapies. Our team is united in their ambition to change lives through medical cannabis. Join us on our journey.
Register your interest in becoming an investor in medicinal cannabis here.
For more on the latest industry trends, legislation and scientific research in exciting new field, take a look at our news section.
One of ANTG’s proprietary medicinal cannabis strains, EVE Cannabis Indica, has been listed on the Australian Register of Therapeutic Goods (ARTG). The ARTG is a reference of therapeutic goods that can lawfully be supplied in or exported from Australia.
In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.